• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of allergy, asthma, and immunology >Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms.
【24h】

Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms.

机译：丙酸氟替卡松鼻腔喷雾剂与孟鲁司特口服液治疗季节性变应性鼻炎症状的比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Few studies have directly compared the efficacy of intranasal corticosteroids with that of leukotriene receptor antagonists for the treatment of daytime and nighttime symptoms of seasonal allergic rhinitis (SAR). OBJECTIVE: To compare fluticasone propionate aqueous nasal spray, 200 microg daily, with oral montelukast, 10 mg daily, for the relief of SAR symptoms. METHODS: Patients with SAR 15 years or older were randomized to receive either fluticasone propionate (n = 367) or montelukast (n = 369) in this double-blind, double-dummy, parallel-group study. The primary efficacy measure was the mean change from baseline in daytime total nasal symptom scores (TNSSs) (the sum of 4 daytime individual nasal symptom scores [INSSs] assessing nasal congestion, itching, rhinorrhea, and sneezing), averaged across weeks 1 and 2. Secondary efficacy measures included the 4 daytime INSSs, nighttime TNSSs (the sum of 3 nighttime INSSs assessing congestion on awakening, difficulty going to sleep, and nighttimeawakenings), and the 3 nighttime INSSs averaged across weeks 1 and 2. RESULTS: Mean changes from baseline in daytime TNSSs (P < .001), all daytime INSSs (P < .001), nighttime TNSSs (P < .001), and all nighttime INSSs (P < or = .02) showed significant differences favoring fluticasone propionate over montelukast across 2 weeks of treatment. CONCLUSION: Compared with montelukast, fluticasone propionate provided significantly greater improvement in daytime and nighttime SAR symptoms.
机译：背景：很少有研究直接比较鼻内皮质类固醇与白三烯受体拮抗剂在治疗季节性变应性鼻炎（SAR）的白天和夜间症状方面的功效。目的：比较每天200微克丙酸氟替卡松鼻腔喷雾剂与每日10mg口服孟鲁司特用于缓解SAR症状的比较。方法：在这项双盲，双模拟，平行组研究中，SAR 15岁或15岁以上的患者被随机分配接受丙酸氟替卡松（n = 367）或孟鲁司特（n = 369）。主要疗效指标是白天总鼻症状分数（TNSSs）（4天评估鼻充血，瘙痒，鼻漏和打喷嚏的个体鼻症状分数[INSSs]的总和）与基线之间的平均变化，在第1周和第2周内平均次要疗效指标包括4个白天INSS，夜间TNSS（3个夜间INSS评估唤醒时的充血，入睡困难和夜间觉醒的总和），以及在第1周和第2周中平均得到的3个夜间INSS。白天TNSS（P <.001），所有白天INSS（P <.001），夜间TNSS（P <.001）和所有夜间INSS（P <或= .02）的基线显示出明显的差异，丙酸氟替卡松优于孟鲁司特经过2周的治疗。结论：与孟鲁司特相比，丙酸氟替卡松在白天和夜间的SAR症状方面均具有更大的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号